By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Media HydeMedia Hyde
  • Home
  • Politics
  • Education
  • Entertainment
  • Sports
  • Blogs
  • Business & Commerce
  • Others
    • Religious
    • Metropolitan
    • Climate and Weather
Font ResizerAa
Media HydeMedia Hyde
Font ResizerAa
  • Home
  • Politics
  • Education
  • Entertainment
  • Sports
  • Blogs
  • Business & Commerce
  • Others
    • Religious
    • Metropolitan
    • Climate and Weather
Follow US
© 2026 Media Hyde Network. All Rights Reserved.
Health

How to Verify Fake and Substandard Medicines? An Easy Method ‎

Last updated: June 29, 2026 9:46 pm
Neha Ashraf
Share
SHARE

The goal of eliminating fake and substandard medicines from the country is moving closer to becoming a reality.

‎According to DRAP sources, a decision has been made to implement the Pharma Track and Trace System across the country during the current year. Under this system, a deadline of October 9 has been set for the implementation of a barcode system on medicine packages.

‎Sources said that formal instructions regarding barcoding and serialization have been issued to pharmaceutical companies nationwide. The Track and Trace System will apply to all companies manufacturing human and veterinary medicines.

‎The responsibility for implementing the system across the country has been assigned to the Drug Regulatory Authority of Pakistan (DRAP). The use of barcodes on medicine packages has been made mandatory for pharmaceutical manufacturers and importers, while companies will be required to include 2D barcodes and serialization data on medicine packs.

‎According to sources, DRAP has sent official communications to PPMA, PVPA, and Pharma Bureau in this regard, while the Pakistan Chemist and Druggist Association has also been informed. Similarly, letters have been issued to provincial Directors General Drug Control and Chief Drug Inspectors.

‎The communication directs pharmaceutical companies to complete all arrangements for implementing the Track and Trace System before October 9. Printing 2D barcodes on medicine packages has been made mandatory for all companies.

‎The federal cabinet has already formally approved the implementation of the Track and Trace System, while amendments to the Drug Labeling and Packing Rules 1978 have also been approved.

‎According to sources, consumers will be able to verify medicines themselves through the 2D barcode printed on the packaging. Under this system, citizens will be able to digitally check medicines, while the barcode system will help identify and eliminate fake and substandard drugs.

‎In addition, it will be possible to verify authentic information regarding a medicine’s expiry date, usage, and price. DRAP has also completed consultations with relevant stakeholders regarding the system.

Share This Article
Email Copy Link Print
Previous Article WHO Reports 1,300 Excess Deaths in Europe Within a Week Due to Heatwave
Next Article Progress Made in Sindh’s Fight Against Polio Virus as Environmental Sample Results Show Significant Improvement
Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Sponsored Ads

Stay Connected

FacebookLike
XFollow
InstagramFollow
YoutubeSubscribe
WhatsAppFollow
ThreadsFollow
Petrol becomes cheaper again as diesel price holds steady
Petrol becomes cheaper again as diesel price holds steady
Business & Commerce Headline
November 17, 2026
PPP rejects forced Sindh split, backs constitutional route for new provinces
PPP rejects forced Sindh split, backs constitutional route for new provinces
Breaking Politics
November 17, 2026
Jamie Dornan admits to shoplifting in his younger days, reveals one rule
Jamie Dornan admits to shoplifting in his younger days, reveals one rule
Entertainment Headline
November 17, 2026
Regional security tops talks between Asim Munir and Turkish air chief
Regional security tops talks between Asim Munir and Turkish air chief
Breaking pakistan
November 17, 2026
EU tightens pressure on Russia with fresh bank and oil sanctions
EU tightens pressure on Russia with fresh bank and oil sanctions
Headline World
November 17, 2026
Saudi firm explores $30bn gas pipeline network for Pakistan
Saudi firm explores $30bn gas pipeline network for Pakistan
Business & Commerce Headline
November 17, 2026

You Might Also Like

Embracing Well-Being in the Workplace: Why a Healthy Workforce Drives Success
BlogHealth

Embracing Well-Being in the Workplace: Why a Healthy Workforce Drives Success

By
Misbah Jogyat
WASHINGTON: UnitedHealth has warned that the Trump administration’s planned Medicare obesity-drug pilot faces “notable challenges,” casting doubt over how smoothly the program can move ahead if major insurers stay cautious. Recent market reporting said the model depends heavily on participation from Medicare drug plans that cover most Part D enrollees, which makes the stance of large insurers especially important. The concern centers on a broader CMS effort to expand access to GLP-1 weight-loss medicines for seniors. Under CMS’s published framework, the longer-term BALANCE Model would begin in Medicare Part D in January 2027, while a temporary Medicare GLP-1 Bridge is designed to start earlier and give eligible beneficiaries short-term access before that main model begins. What makes this a little more complicated is that the short-term bridge and the longer pilot are not the same thing. CMS says the Medicare GLP-1 Bridge operates outside the normal Part D coverage and payment flow, meaning Part D sponsors are not directly involved in that bridge arrangement. In other words, insurer participation is a much bigger issue for the 2027 BALANCE rollout than for the bridge itself. That distinction matters because investors and drugmakers are watching this closely. Reports said shares of obesity-drug makers fell after UnitedHealth’s comments, largely because Medicare coverage is seen as a huge growth opportunity for drugs such as Wegovy and Zepbound. If major insurers hesitate, the program could struggle to achieve the scale CMS appears to want. There is already some evidence of resistance. MarketWatch reported that CVS Health has opted out, while UnitedHealth is still evaluating the structure and discussing possible changes with Medicare officials. That does not mean the program is dead, not yet anyway, but it does suggest the administration may need to revise the design or sweeten the terms if it wants broader insurer buy-in. The bigger backdrop here is cost. Medicare has long been wary of broad obesity-drug coverage because GLP-1 therapies are expensive and potentially involve very large patient populations. Earlier policy debates around these drugs were shaped by concerns that wide coverage could drive up federal spending sharply, even as supporters argued the medicines could reduce longer-term health costs tied to obesity. So the headline problem for CMS is pretty straightforward: it has created a short-term bridge that can move without direct Part D plan involvement, but the more ambitious long-term Medicare model still appears to need insurers on board. UnitedHealth’s warning does not shut the door, but it does signal that one of the industry’s biggest players thinks the current setup may not be ready for easy launch.
HeadlineHealth

UnitedHealth raises red flags over Medicare obesity-drug pilot

By
Mabruka Khan
Health

Working Long Hours May Physically Change Your Brain, Study Finds

By
Fatima Nadeem
Health

New Investment in Pharmaceutical Industry Begins, $10 Million Project for Advanced Drug Production

By
Neha Ashraf
Media Hyde Media Hyde Dark
Facebook Twitter Youtube Rss Medium

About US

Media Hyde Network: Your instant connection to breaking stories and live updates. Stay informed with our real-time coverage across politics, tech, entertainment, and more. Your reliable source for 24/7 News.

Top Categories
  • Headline
  • Politics
  • Entertainment
  • Education
  • Sports
  • Religious
  • Metropolitan
  • Climate and Weather
Usefull Links
  • Contact Us
  • Disclaimer
  • Privacy Policy
  • Cookies Policy
  • Advertising Policy
  • Terms & Conditions

© 2025 Media Hyde Network. All Rights Reserved.

Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?